Literature DB >> 1387818

Automated measurement of lipoprotein(a) by immunoturbidimetric analysis.

D M Levine1, B J Sloan, J E Donner, J D Lorenz, R H Heinzerling.   

Abstract

Immunoturbidimetric analysis of lipoprotein(a) in plasma or serum was developed for use on the Roche COBAS FARA II and COBAS MIRA clinical chemistry analyzers. The components of the assay are: (1) buffer consisting of 2.25% polyethylene glycol in phosphate-buffered saline, 0.2% gelatin, and a surfactant; (2) fractionated goat anti-human lipoprotein(a) IgG; (3) five standards with lipoprotein(a) concentrations ranging from 0.05 to 1.0 g/l; (4) two controls with concentrations of approximately 0.2 and 0.5 g/l. The analyzer delivers sample and buffer, incubates the reaction mixture at 37 degrees C for 5 min, delivers neat lipoprotein(a) antibody, and incubates for an additional 10 min. The lipoprotein(a) concentration of samples is calculated by the COBAS DENS (Data Evaluation for Non-linear Standard Curves) option by fitting the standard curve values to a four-parameter logit-log curve model. Total imprecision results (CV%) for the FARA II and MIRA were under 11% (NCCLS protocol EP5-T). The assay is linear beyond the highest calibrator to 2.6 g/l. No interference was observed for plasminogen up to 2.3 g/l, apolipoprotein B up to 4.36 g/l, hemoglobin up to 10 g/l, bilirubin up to 4.0 g/l, and triglycerides up to 4.36 g/l. Comparison with a double monoclonal ELISA used at the Northwest Lipid Research Laboratories yielded: R = 0.970, slope = 1.013, and y-intercept = 0.00009 (n = 37). Comparison with a commercially available ELISA kit for lipoprotein(a) yielded: r = 0.987, slope = 1.243, and y-intercept = 0.024 (n = 40). This assay provides rapid, accurate, and precise screening of lipoprotein(a) in serum or plasma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387818     DOI: 10.1007/bf02591419

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  6 in total

1.  Application of machine learning algorithms to predict coronary artery calcification with a sibship-based design.

Authors:  Yan V Sun; Lawrence F Bielak; Patricia A Peyser; Stephen T Turner; Patrick F Sheedy; Eric Boerwinkle; Sharon L R Kardia
Journal:  Genet Epidemiol       Date:  2008-05       Impact factor: 2.135

2.  Lipoprotein (a): Examination of Cardiovascular Risk in a Pediatric Referral Population.

Authors:  Omar Qayum; Noor Alshami; Chizitam F Ibezim; Kimberly J Reid; Janelle R Noel-MacDonnell; Geetha Raghuveer
Journal:  Pediatr Cardiol       Date:  2018-06-13       Impact factor: 1.655

3.  Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults.

Authors:  Azadeh Beheshtian; Sanyog G Shitole; Alan Z Segal; Dana Leifer; Russell P Tracy; Daniel J Rader; Richard B Devereux; Jorge R Kizer
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

4.  Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis.

Authors:  Teresa Trenkwalder; Christopher P Nelson; Muntaser D Musameh; Ify R Mordi; Thorsten Kessler; Costanza Pellegrini; Radoslaw Debiec; Tobias Rheude; Viktor Lazovic; Lingyao Zeng; Andreas Martinsson; J Gustav Smith; Jesper R Gådin; Anders Franco-Cereceda; Per Eriksson; Jonas B Nielsen; Sarah E Graham; Cristen J Willer; Kristian Hveem; Adnan Kastrati; Peter S Braund; Colin N A Palmer; Amparo Aracil; Oliver Husser; Wolfgang Koenig; Heribert Schunkert; Chim C Lang; Christian Hengstenberg; Nilesh J Samani
Journal:  Int J Cardiol       Date:  2018-11-17       Impact factor: 4.164

5.  Gemfibrozil and Mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol--pilot study.

Authors:  G Simoni; A Gianotti; A Ardia; A Baiardi; D Civalleri
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

6.  Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma.

Authors:  Mario Uccello; Giulia Malaguarnera; Elisa M Pelligra; Antonio Biondi; Francesco Basile; Massimo Motta
Journal:  Indian J Med Paediatr Oncol       Date:  2011-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.